Activation of the NRF2 antioxidant program sensitizes tumors to G6PD inhibition
Hongyu Ding, Zihong Chen, Katherine Wu, Shih Ming Huang, Warren Wu, Sarah E. LeBoeuf, Ray Pillai, Joshua D. Rabinowitz, Thales Papagiannakopoulos
Abstract
mutant tumor growth, and this suppression was further augmented by TCA depletion by glutaminase inhibition. Thus, G6PD inhibition–induced TCA depletion is a therapeutic vulnerability of NRF2-activated cancer.
Topics & Concepts
AntioxidantCancer researchChemistryGrowth inhibitionCell biologyBiochemistryBiologyCell growthGenomics, phytochemicals, and oxidative stress